OTCMKTS:ENZN - Enzon Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.24 0.00 (0.00 %)
(As of 10/15/2018 04:00 PM ET)
Previous Close$0.24
Today's Range$0.24 - $0.2598
52-Week Range$0.03 - $0.3350
Volume22,764 shs
Average Volume56,828 shs
Market Capitalization$10.56 million
P/E RatioN/A
Dividend YieldN/A
Beta0.79
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey.

Receive ENZN News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:ENZN
CUSIP29390410
Phone732-980-4500

Debt

Debt-to-Equity RatioN/A
Current Ratio19.11
Quick Ratio19.11

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$8.38 million
Price / Sales1.27
Cash Flow$0.1237 per share
Price / Cash1.94
Book Value$0.21 per share
Price / Book1.14

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$5.44 million
Net Margins40.42%
Return on Equity1.10%
Return on Assets1.05%

Miscellaneous

Employees5
Outstanding Shares44,220,000
Market Cap$10.56 million

Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions

What is Enzon Pharmaceuticals' stock symbol?

Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN."

How were Enzon Pharmaceuticals' earnings last quarter?

Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) posted its quarterly earnings results on Friday, August, 10th. The biotechnology company reported ($0.01) EPS for the quarter. The biotechnology company earned $0.06 million during the quarter. Enzon Pharmaceuticals had a net margin of 40.42% and a return on equity of 1.10%. View Enzon Pharmaceuticals' Earnings History.

When is Enzon Pharmaceuticals' next earnings date?

Enzon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 8th 2018. View Earnings Estimates for Enzon Pharmaceuticals.

Who are some of Enzon Pharmaceuticals' key competitors?

Who are Enzon Pharmaceuticals' key executives?

Enzon Pharmaceuticals' management team includes the folowing people:
  • Mr. Andrew Rackear, CEO & Sec. (Age 64)
  • Mr. Richard L. Feinstein, VP of Fin. & CFO (Age 75)

How do I buy shares of Enzon Pharmaceuticals?

Shares of ENZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzon Pharmaceuticals' stock price today?

One share of ENZN stock can currently be purchased for approximately $0.24.

How big of a company is Enzon Pharmaceuticals?

Enzon Pharmaceuticals has a market capitalization of $10.56 million and generates $8.38 million in revenue each year. Enzon Pharmaceuticals employs 5 workers across the globe.

What is Enzon Pharmaceuticals' official website?

The official website for Enzon Pharmaceuticals is http://www.enzon.com.

How can I contact Enzon Pharmaceuticals?

Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at [email protected]


MarketBeat Community Rating for Enzon Pharmaceuticals (OTCMKTS ENZN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  109
MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel